Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

Inzucchi, 2012, Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, 55, 1577, 10.1007/s00125-012-2534-0 2013, Standards of medical care in diabetes—2013, Diabetes Care, 36, S11 Morgan, 2012, What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes, J Clin Endocrinol Metab, 97, 4605, 10.1210/jc.2012-3034 DeFronzo, 2009, Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus, Diabetes, 58, 773, 10.2337/db09-9028 Hauber, 2009, Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents, Diabet Med, 26, 416, 10.1111/j.1464-5491.2009.02696.x Moghissi, 2013, Hypoglycemia: minimizing its impact in type 2 diabetes, Endocr Pract, 19, 526, 10.4158/EP13005.RA DeFronzo, 2012, The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia, Diabetes Obes Metab, 14, 5, 10.1111/j.1463-1326.2011.01511.x Barnett, 2013, Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus, Postgrad Med, 125, 92, 10.3810/pgm.2013.09.2698 Basile, 2013, The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM), J Diabetes Complications, 27, 280, 10.1016/j.jdiacomp.2012.12.004 Grempler, 2012, Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors, Diabetes Obes Metab, 14, 83, 10.1111/j.1463-1326.2011.01517.x Roden, 2013, Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Diabetes Endocrinol, 1, 208, 10.1016/S2213-8587(13)70084-6 Häring, 2014, Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial, Diabetes Care, 37, 1650, 10.2337/dc13-2105 Häring, 2013, Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial, Diabetes Care, 36, 3396, 10.2337/dc12-2673 Kovacs, 2014, Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial, Diabetes Obes Metab, 16, 147, 10.1111/dom.12188 Ridderstrale, 2013, Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control, Cardiovasc Diabetol, 12, 129, 10.1186/1475-2840-12-129 Ferrannini, 2013, A Phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes, Diabetes Obes Metab, 15, 721, 10.1111/dom.12081 Rosenstock, 2013, Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia, Diabetes Obes Metab, 15, 1154, 10.1111/dom.12185 Ferrannini, 2013, Long-term safety and efficacy of empagliflozin, sitagliptin and metformin: an active-controlled, parallel group, randomized, 78-week open-label extension study in patients with type 2 diabetes, Diabetes Care, 36, 4015, 10.2337/dc13-0663 Fidler, 2011, Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs, J Med Econ, 14, 646, 10.3111/13696998.2011.610852 Gastaldelli, 2007, Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects, Gastroenterology, 133, 496, 10.1053/j.gastro.2007.04.068 Gastaldelli, 2002, Metabolic effects of visceral fat accumulation in type 2 diabetes, J Clin Endocrinol Metab, 87, 5098, 10.1210/jc.2002-020696 Bolinder, 2014, Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin, Diabetes Obes Metab, 16, 159, 10.1111/dom.12189 Cefalu, 2013, Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial, Lancet, 382, 941, 10.1016/S0140-6736(13)60683-2 Musso, 2012, A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials, Ann Med, 44, 375, 10.3109/07853890.2011.560181 Nathan, 2009, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 32, 193, 10.2337/dc08-9025 Hirst, 2013, Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis, Diabetologia, 56, 973, 10.1007/s00125-013-2856-6 Scholz, 2001, Efficacy and tolerability of glimepiride in daily practice, Clin Drug Invest, 21, 597, 10.2165/00044011-200121090-00001 Nauck, 2011, Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial, Diabetes Care, 34, 2015, 10.2337/dc11-0606